A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

ClinicalTrials.gov ID: NCT05193409

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05193409. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).

Study identification

NCT ID: NCT05193409
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bionomics Limited; Industry
Enrollment: 151 participants

Conditions and interventions

Conditions

Social Anxiety Disorder

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2, 2022 (Actual)
Primary completion: Oct 10, 2022 (Actual)
Completion: Oct 17, 2022 (Actual)
Last update posted: Mar 18, 2025

2022

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
PREVAIL Study Clinical Trial Site	Beverly Hills	California	90210	—
PREVAIL Study Clinical Trial Site	Encino	California	91316	—
PREVAIL Study Clinical Trial Site	Glendale	California	91204	—
PREVAIL Study Clinical Trial Site	New Haven	Connecticut	33122	—
PREVAIL Study Clinical Trial Site	Lauderhill	Florida	33319	—
PREVAIL Study Clinical Trial Site	Miami	Florida	33122	—
PREVAIL Study Clinical Trial Site	Miami Lakes	Florida	33016	—
PREVAIL Study Clinical Trial Site	Decatur	Georgia	30030	—
PREVAIL Study Clinical Trial Site	Prairie Village	Kansas	66208	—
PREVAIL Study Clinical Trial Site	Boston	Massachusetts	02114	—
PREVAIL Study Clinical Trial Site	Princeton	New Jersey	08540	—
PREVAIL Study Clinical Trial Site	Brooklyn	New York	11229	—
PREVAIL Study Clinical Trial Site	Charlotte	North Carolina	28211	—
PREVAIL Study Clinical Trial Site	Cincinnati	Ohio	45212	—
PREVAIL Study Clinical Trial Site	Draper	Utah	84020	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05193409, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 18, 2025 · Synced Nov 15, 2026